$ISCO
International Stem Cell CORP

2018 Q1 Form 10-Q Financial Statement

#000156459018014035 Filed on May 21, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q4 2017 Q1
Revenue $2.633M $1.840M $2.010M
YoY Change 31.0% 8.88% 24.07%
Cost Of Revenue $825.0K $620.0K $550.0K
YoY Change 50.0% 34.78% 44.74%
Gross Profit $1.808M $1.220M $1.450M
YoY Change 24.69% -1.61% 16.94%
Gross Profit Margin 68.67% 66.3% 72.14%
Selling, General & Admin $2.182M $2.500M $1.853M
YoY Change 17.75% 53.37% 2.94%
% of Gross Profit 120.69% 204.92% 127.79%
Research & Development $811.0K $600.0K $645.0K
YoY Change 25.74% -20.0% 11.21%
% of Gross Profit 44.86% 49.18% 44.48%
Depreciation & Amortization $68.00K $80.00K $82.00K
YoY Change -17.07% 0.0% -4.65%
% of Gross Profit 3.76% 6.56% 5.66%
Operating Expenses $2.993M $3.150M $2.498M
YoY Change 19.82% 31.25% 4.08%
Operating Profit -$1.185M -$1.930M -$1.048M
YoY Change 13.07% 66.38% -9.66%
Interest Expense $350.0K $540.0K $6.000K
YoY Change 5733.33% -83.78% 20.0%
% of Operating Profit
Other Income/Expense, Net $355.0K $0.00 $0.00
YoY Change -100.0%
Pretax Income -$830.0K -$1.390M -$3.084M
YoY Change -73.09% -164.35% -78.84%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$830.0K -$1.390M -$3.080M
YoY Change -73.05% -164.35% -78.86%
Net Earnings / Revenue -31.52% -75.54% -153.23%
Basic Earnings Per Share
Diluted Earnings Per Share -$135.2K -$297.6K -$779.7K
COMMON SHARES
Basic Shares Outstanding 3.951M
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q1 2017 Q4 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $450.0K $300.0K $680.0K
YoY Change -33.82% 172.73% -55.84%
Cash & Equivalents $450.0K $304.0K $680.0K
Short-Term Investments
Other Short-Term Assets $640.0K $780.0K $560.0K
YoY Change 14.29% 85.71% -20.0%
Inventory $1.390M $1.307M $1.420M
Prepaid Expenses
Receivables $940.0K $465.0K $620.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $3.410M $2.855M $3.270M
YoY Change 4.28% 14.57% -20.82%
LONG-TERM ASSETS
Property, Plant & Equipment $340.0K $321.0K $360.0K
YoY Change -5.56% -18.94% -5.26%
Goodwill
YoY Change
Intangibles $2.922M
YoY Change -16.13%
Long-Term Investments
YoY Change
Other Assets $790.0K $770.0K $700.0K
YoY Change 12.86% 14.93% 32.08%
Total Long-Term Assets $4.060M $4.009M $4.590M
YoY Change -11.55% -12.04% 7.75%
TOTAL ASSETS
Total Short-Term Assets $3.410M $2.855M $3.270M
Total Long-Term Assets $4.060M $4.009M $4.590M
Total Assets $7.470M $6.864M $7.860M
YoY Change -4.96% -2.64% -6.32%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.610M $830.0K $730.0K
YoY Change 120.55% -1.19% 21.67%
Accrued Expenses $860.0K $607.0K $860.0K
YoY Change 0.0% 29.15% 13.16%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.830M $4.800M $7.220M
YoY Change -19.25% 33.3% -66.01%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $5.830M $4.800M $7.220M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $5.830M $4.800M $7.220M
YoY Change -19.25% 33.33% -66.01%
SHAREHOLDERS EQUITY
Retained Earnings -$105.4M -$104.5M
YoY Change 6.16%
Common Stock $6.000K
YoY Change 50.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $1.639M $2.064M $640.0K
YoY Change
Total Liabilities & Shareholders Equity $7.468M $6.864M $7.860M
YoY Change -4.99% -2.57% -6.32%

Cashflow Statement

Concept 2018 Q1 2017 Q4 2017 Q1
OPERATING ACTIVITIES
Net Income -$830.0K -$1.390M -$3.080M
YoY Change -73.05% -164.35% -78.86%
Depreciation, Depletion And Amortization $68.00K $80.00K $82.00K
YoY Change -17.07% 0.0% -4.65%
Cash From Operating Activities -$48.00K -$490.0K -$570.0K
YoY Change -91.58% -47.87% -71.07%
INVESTING ACTIVITIES
Capital Expenditures $57.00K -$210.0K $8.000K
YoY Change 612.5% 16.67% -86.89%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$201.0K -$210.0K -$160.0K
YoY Change 25.63% 16.67% -27.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $500.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 392.0K 500.0K 1.300M
YoY Change -69.85% 0.0% -59.38%
NET CHANGE
Cash From Operating Activities -48.00K -490.0K -570.0K
Cash From Investing Activities -201.0K -210.0K -160.0K
Cash From Financing Activities 392.0K 500.0K 1.300M
Net Change In Cash 143.0K -200.0K 570.0K
YoY Change -74.91% -67.74% -43.56%
FREE CASH FLOW
Cash From Operating Activities -$48.00K -$490.0K -$570.0K
Capital Expenditures $57.00K -$210.0K $8.000K
Free Cash Flow -$105.0K -$280.0K -$578.0K
YoY Change -81.83% -63.16% -71.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
708000
CY2018Q1 us-gaap Cost Of Revenue
CostOfRevenue
825000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1474000
CY2017Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3084000
CY2018Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-355000
CY2017Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3084000
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.78
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3952000
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
3444000
CY2017Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
2032000
CY2017Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
576000
CY2018Q1 us-gaap Cash
Cash
447000
CY2017Q4 us-gaap Cash
Cash
304000
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6195160
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7468000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
1639000
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6195160
CY2018Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
12000
CY2017Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
645000
CY2018Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
811000
CY2017Q1 us-gaap Interest Expense
InterestExpense
6000
CY2018Q1 isco Miscellaneous Income Expense
MiscellaneousIncomeExpense
2000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
355000
CY2018Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-830000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-830000
CY2018Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-830000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6136000
CY2017 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
49000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
500000
CY2017 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
2756000
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1384000
CY2018Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
8000
CY2018Q1 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
90000
CY2018Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
68000
CY2017Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
82000
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
307000
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
254000
CY2018Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
8000
CY2017Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
24000
CY2018Q1 isco Inventory Adjustment
InventoryAdjustment
3000
CY2017Q1 isco Inventory Adjustment
InventoryAdjustment
11000
CY2018Q1 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
1000
CY2018Q1 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-1000
CY2018Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
111000
CY2017Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
80000
CY2018Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
474000
CY2017Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
41000
CY2018Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
105000
CY2017Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
71000
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-137000
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
142000
CY2018Q1 us-gaap Increase Decrease In Deposits Outstanding
IncreaseDecreaseInDepositsOutstanding
1000
CY2018Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
782000
CY2017Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-116000
CY2018Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
299000
CY2017Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
395000
CY2017Q1 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
5000
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-48000
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-571000
CY2018Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
57000
CY2017Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8000
CY2018Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
144000
CY2017Q1 us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
155000
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-105362000
CY2018Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
719000
CY2017Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
692000
CY2017Q1 us-gaap Costs And Expenses
CostsAndExpenses
3051000
CY2018Q1 us-gaap Costs And Expenses
CostsAndExpenses
3818000
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1277000
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-6069000
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-201000
CY2017Q1 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-163000
CY2018Q1 isco Proceeds From Bridge Loan From Related Party
ProceedsFromBridgeLoanFromRelatedParty
350000
CY2017Q1 isco Proceeds From Bridge Loan From Related Party
ProceedsFromBridgeLoanFromRelatedParty
1300000
CY2018Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
90000
CY2018Q1 isco Payments On Financed Insurance Premiums
PaymentsOnFinancedInsurancePremiums
48000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
392000
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
1300000
CY2018Q1 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
143000
CY2017Q1 us-gaap Cash Period Increase Decrease
CashPeriodIncreaseDecrease
566000
CY2016Q4 us-gaap Cash
Cash
110000
CY2017Q1 us-gaap Cash
Cash
676000
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements. Significant estimates include patent life (remaining legal life versus remaining useful life), inventory carrying values, allowance for excess and obsolete inventories, allowance for sales returns and doubtful accounts, and transactions using the Black-Scholes option pricing model, e.g., warrants and stock options, as well as the Monte-Carlo valuation method for certain warrants. Actual results could differ from those estimates. </p></div>
CY2018Q1 isco Burn Rate Excluding Capital Expenditures And Patent Costs
BurnRateExcludingCapitalExpendituresAndPatentCosts
16000
CY2006Q3 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
133334
CY2018Q1 isco Percentage Of Ownership In Issue And Outstanding Share Of Common Stock Parent Company
PercentageOfOwnershipInIssueAndOutstandingShareOfCommonStockParentCompany
0.937
CY2018Q1 isco Capital Expenditures And Patent Costs
CapitalExpendituresAndPatentCosts
67000
CY2018Q1 isco Revenue Generating Subsidiaries
RevenueGeneratingSubsidiaries
2
CY2018Q1 isco Maximum Original Maturities Period
MaximumOriginalMaturitiesPeriod
P3M
CY2017Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
609000
CY2018Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
537000
CY2018Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2017Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2018Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3796000
CY2017Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
3763000
CY2018Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
868000
CY2017Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
841000
CY2018Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2018Q1 us-gaap Revenue Performance Obligation Description Of Payment Terms
RevenuePerformanceObligationDescriptionOfPaymentTerms
The Company's revenue consists primarily of sales of products from its two revenue-generating operating segments, the cosmetics products and biomedical products business segments. The cosmetic market segment markets and sells a line of luxury skincare products sold through three sales channels: ecommerce, professional, and international. The ecommerce channel sells direct to customers through online orders, while the professional sales are to spas, salons and other skincare providers. International sales are primarily through distributors. The biomedical market segment markets and sells primary human cell research products with two product categories, cells and media, sold both within and outside the United States.
CY2018Q1 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
1054230
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
422676
CY2018Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
2040596
CY2017Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1534246
CY2018Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3951052
CY2017Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4001469
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35
CY2018Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2018Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
630000
CY2017Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
472000
CY2018Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1170000
CY2017Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1154000
CY2018Q1 us-gaap Inventory Gross
InventoryGross
2337000
CY2017Q4 us-gaap Inventory Gross
InventoryGross
2235000
CY2018Q1 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
233000
CY2017Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
236000
CY2018Q1 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
2104000
CY2017Q4 isco Inventory Net Current And Noncurrent
InventoryNetCurrentAndNoncurrent
1999000
CY2018Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2962000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2907000
CY2018Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2626000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2586000
CY2018Q1 us-gaap Depreciation
Depreciation
41000
CY2017Q1 us-gaap Depreciation
Depreciation
49000
CY2004Q1 us-gaap License Costs
LicenseCosts
22500
CY2004Q2 us-gaap License Costs
LicenseCosts
400000
CY2018Q1 isco Finite Lived Patents And Trademarks Gross
FiniteLivedPatentsAndTrademarksGross
3049000
CY2018Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
39000
CY2018Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
78000
CY2018Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
61000
CY2018Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
61000
CY2018Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
98000
CY2018Q1 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
2508000
CY2018Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
2845000
CY2008Q2 isco Advances From Nonaffiliated Collaboration
AdvancesFromNonaffiliatedCollaboration
250000
CY2008Q2 isco Specified Amount Of Revenue To Be Utilized First For Advances
SpecifiedAmountOfRevenueToBeUtilizedFirstForAdvances
250000
CY2018Q1 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
0
CY2018Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000
CY2018Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2008Q2 isco Number Of Accredited Investors
NumberOfAccreditedInvestors
5
CY2017Q4 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
2700000
CY2017Q4 isco Debt Conversion Converted Instrument Amount Of Accrued Interest
DebtConversionConvertedInstrumentAmountOfAccruedInterest
56000
CY2017Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
500000
CY2018Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13858211
CY2018Q1 isco Related Party Rent Expense
RelatedPartyRentExpense
40000
CY2017Q1 isco Related Party Rent Expense
RelatedPartyRentExpense
38000
CY2018Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 isco Net Decrease In Deferred Tax Assets
NetDecreaseInDeferredTaxAssets
8819000
CY2017 isco Increase In Deferred Tax Assets
IncreaseInDeferredTaxAssets
724000
CY2017 isco Tax Cuts And Jobs Act Of2017 Change In Tax Rate Decrease In Deferred Tax Assets
TaxCutsAndJobsActOf2017ChangeInTaxRateDecreaseInDeferredTaxAssets
9543000
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
307000
CY2017Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
254000
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2500000
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
CY2013Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
67500
CY2013Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
33750
CY2013Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
30.00
CY2013Q1 isco Warrant Term
WarrantTerm
P5Y
CY2018Q1 invest Investment Warrants Expiration Date
InvestmentWarrantsExpirationDate
2018-01-31
CY2013Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
16667
CY2013Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
33334
CY2013Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
30.00
CY2016Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7321468
CY2017 isco Warrant Forfeited Or Cancelled
WarrantForfeitedOrCancelled
3319999
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4001469
CY2018Q1 isco Warrant Forfeited Or Cancelled
WarrantForfeitedOrCancelled
50417
CY2017 isco Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Forfeited
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeited
1.75
CY2018Q1 isco Class Of Warrant Or Right Exercise Price Of Warrants Or Rights Forfeited
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsForfeited
30.00
CY2018Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.75
CY2018Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
87000
CY2017Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
85000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
347000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
416000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
287000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
267000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
143000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
85000
CY2018Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1545000
CY2018Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
3
CY2018Q1 isco Number Of Business Units
NumberOfBusinessUnits
2
CY2018Q1 isco Number Of Products
NumberOfProducts
190

Files In Submission

Name View Source Status
0001564590-18-014035-index-headers.html Edgar Link pending
0001564590-18-014035-index.html Edgar Link pending
0001564590-18-014035.txt Edgar Link pending
0001564590-18-014035-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
isco-10q_20180331.htm Edgar Link pending
isco-20180331.xml Edgar Link completed
isco-20180331.xsd Edgar Link pending
isco-20180331_cal.xml Edgar Link unprocessable
isco-20180331_def.xml Edgar Link unprocessable
isco-20180331_lab.xml Edgar Link unprocessable
isco-20180331_pre.xml Edgar Link unprocessable
isco-ex311_7.htm Edgar Link pending
isco-ex312_6.htm Edgar Link pending
isco-ex321_9.htm Edgar Link pending
isco-ex322_8.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending